Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q11163063> ?p ?o }
Showing triples 1 to 49 of
49
with 100 triples per page.
- Q11163063 subject Q8248734.
- Q11163063 subject Q8341873.
- Q11163063 subject Q8375173.
- Q11163063 subject Q8546974.
- Q11163063 abstract "7-methoxy-1-(2-morpholinoethyl)-N-((1S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (N-[(S)-fenchyl]-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide, UR-12, MN-25) is a drug invented by Bristol-Myers Squibb, that acts as a reasonably selective agonist of peripheral cannabinoid receptors. It has moderate affinity for CB2 receptors with a Ki of 11nM, but 22x lower affinity for the psychoactive CB1 receptors with a Ki of 245nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a Ki of 8nM at CB1 and 29nM at CB2, which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB2 (cf. JWH-018 vs JWH-007, JWH-081 vs JWH-098).Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid, Org 28611, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in JWH-200 or A-796,260. Early compounds such as these have subsequently led to the development of a large number of related indole-3-carboxamide cannabinoid ligands.".
- Q11163063 casNumber "501926-82-5".
- Q11163063 casSupplemental "501927-29-3 (2-methyl derivative)".
- Q11163063 fdaUniiCode "8WXU5YRE25".
- Q11163063 iupacName "7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide".
- Q11163063 pubchem "44307202".
- Q11163063 thumbnail UR-12_structure.png?width=300.
- Q11163063 wikiPageWikiLink Q17907844.
- Q11163063 wikiPageWikiLink Q21163314.
- Q11163063 wikiPageWikiLink Q265940.
- Q11163063 wikiPageWikiLink Q266423.
- Q11163063 wikiPageWikiLink Q389934.
- Q11163063 wikiPageWikiLink Q4041745.
- Q11163063 wikiPageWikiLink Q419020.
- Q11163063 wikiPageWikiLink Q421237.
- Q11163063 wikiPageWikiLink Q4646876.
- Q11163063 wikiPageWikiLink Q4646879.
- Q11163063 wikiPageWikiLink Q4649999.
- Q11163063 wikiPageWikiLink Q4652482.
- Q11163063 wikiPageWikiLink Q6109071.
- Q11163063 wikiPageWikiLink Q6109172.
- Q11163063 wikiPageWikiLink Q6109184.
- Q11163063 wikiPageWikiLink Q6109214.
- Q11163063 wikiPageWikiLink Q6715116.
- Q11163063 wikiPageWikiLink Q7101738.
- Q11163063 wikiPageWikiLink Q7392759.
- Q11163063 wikiPageWikiLink Q7865583.
- Q11163063 wikiPageWikiLink Q8248734.
- Q11163063 wikiPageWikiLink Q8341873.
- Q11163063 wikiPageWikiLink Q8375173.
- Q11163063 wikiPageWikiLink Q8546974.
- Q11163063 wikiPageWikiLink Q898254.
- Q11163063 casNumber "501926".
- Q11163063 casSupplemental "501927".
- Q11163063 iupacName "7".
- Q11163063 pubchem "44307202".
- Q11163063 unii "8".
- Q11163063 type ChemicalSubstance.
- Q11163063 type Drug.
- Q11163063 type ChemicalObject.
- Q11163063 type Thing.
- Q11163063 type Q8386.
- Q11163063 comment "7-methoxy-1-(2-morpholinoethyl)-N-((1S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (N-[(S)-fenchyl]-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide, UR-12, MN-25) is a drug invented by Bristol-Myers Squibb, that acts as a reasonably selective agonist of peripheral cannabinoid receptors. It has moderate affinity for CB2 receptors with a Ki of 11nM, but 22x lower affinity for the psychoactive CB1 receptors with a Ki of 245nM.".
- Q11163063 label "N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide".
- Q11163063 depiction UR-12_structure.png.